Literature DB >> 10438578

MHC-I-induced apoptosis in human B-lymphoma cells is dependent on protein tyrosine and serine/threonine kinases.

A E Pedersen1, S Bregenholt, B Johansen, S Skov, M H Claesson.   

Abstract

In addition to providing the framework for peptide presentation, major histocompatibility complex class I (MHC-I) molecules can act as signal transducing molecules in lymphoid cells. Here we show that the mobilization of intracellular calcium, which follows crosslinking of MHC-I molecules on human B lymphoma cells, is dependent on protein tyrosine kinases and the phosphatidylinositol 3 (PI-3) kinase. Functional studies showed that MHC-I crosslinking induced almost complete inhibition of the spontaneous proliferation of the B lymphoma cells as early as 6 h post-crosslinking and apoptosis 24 h post-crosslinking. Preincubation with either protein tyrosine kinase or protein serine/threonine kinase inhibitors reduced the MHC-I-induced apoptosis to background levels, whereas inhibition of PI-3 kinase had no effect. These data demonstrate a pivotal role for protein tyrosine and serine/threonine kinases in MHC-I-mediated apoptosis in human B-cells and suggest the presence of several MHC-I signaling pathways leading to diverse effects in these cells. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438578     DOI: 10.1006/excr.1999.4571

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  2 in total

1.  Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway.

Authors:  Runjia Fu; Xiaohong Wang; Ying Hu; Hong Du; Bin Dong; Sheng Ao; Li Zhang; Zhijian Sun; Lianhai Zhang; Guoqing Lv; Jiafu Ji
Journal:  Int J Oncol       Date:  2019-03-12       Impact factor: 5.650

Review 2.  Reverse Signaling by MHC-I Molecules in Immune and Non-Immune Cell Types.

Authors:  Elke M Muntjewerff; Luca D Meesters; Geert van den Bogaart; Natalia H Revelo
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.